Is BAC a buy, hold, or sell?
BAC carries a valuation grade of Buy. The trailing P/E of 13.5 sits broadly in line with the Financials sector median of 14.0x. Our discounted cash flow model produces an intrinsic range of $57–$77 — implying a +23% margin of safety at the current price of $54.54. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
BAC has beaten consensus estimates in 80% of recent quarters, signalling strong execution consistency. The most recent quarter delivered a 8.8% earnings surprise. Analyst estimate revisions are trending upward.
What are BAC's key risk factors?
With a beta of 1.20, BAC exhibits an above-market risk profile relative to the broad market. The 95th-percentile CVaR of -12.6% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.3% of total portfolio loss in the worst 5% of months. Net margins stand at 29.0%.
Implied volatility of 3.9% is below realized volatility of 19.7%, potentially making options relatively cheap. Insiders have been net sellers to the tune of $10928.5M recently. While routine dispositions are common, the magnitude bears watching.
How does BAC fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — BAC carries a beta of 1.20, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all buyings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, BAC shows the strongest co-movement with WFC (0.80), C (0.76), JPM (0.74). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios. With the top peer correlation at 0.80, adding BAC to a portfolio that already buys these names provides limited marginal diversification benefit — particularly during stress events when correlations converge toward 1.0.
True portfolio risk is a function of the full covariance structure across all buyings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The BAC analysis here is a single node in that larger structure.
For our full conviction hierarchy across alternative asset managers — including BAC's positioning in the 2026 private credit stress test — see: Private Equity 2026: $265B Crisis — Why Blackstone & KKR Lead. For the BDC redemption mechanics and fund-level data underpinning these ratings: Private Credit 2026: BDC Liquidity Crisis & Systemic Stress Test →
